Evidence map›Paper›PMID 30296259›Full record

ArticlePLoS neglected tropical diseases2018

Identifying a sufficient core group for trachoma transmission.

Thomas M Lietman, Michael S Deiner, Catherine E Oldenburg, Scott D Nash, Jeremy D Keenan, Travis C Porco

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Trachoma.Nature reviews. Disease primers · 2022
    Review
  3. Article
  4. Article
  5. Long-distance truck drivers and the increasing risk of COVID-19 spread in Uganda.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2020
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Thomas M LietmanF.I. Proctor Foundation, University of California San Francisco, San Francisco, CA, United States of America.ORCID 0000-0001-8216-0240
Michael S DeinerF.I. Proctor Foundation, University of California San Francisco, San Francisco, CA, United States of America.
Catherine E OldenburgF.I. Proctor Foundation, University of California San Francisco, San Francisco, CA, United States of America.
Scott D NashTrachoma Control Program, The Carter Center, Atlanta, Georgia, United States of America.
Jeremy D KeenanF.I. Proctor Foundation, University of California San Francisco, San Francisco, CA, United States of America.
Travis C PorcoF.I. Proctor Foundation, University of California San Francisco, San Francisco, CA, United States of America.
University of California, San Francisco · USCarter Center · US

Funding

Rapid-Prototyping and Design CoreP30EY002162 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LAKKARAJU, APARNA · 1985 to 2024
$16.8M
The Brown Initiative in HIV and AIDS Clinical Research for Minority CommunitiesR25MH083620 · NIMH · MIRIAM HOSPITAL · PI NUNN, AMY STEWART · 2008 to 2025
$3.7M
Forecasting Trachoma Control - Diversity SupplementR01EY025350 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI THOMAS M LIETMAN, Travis Christian Porco · 2016 to 2026
$3.3M
Kebele Elimination of Trachoma for Ocular HealthUG1EY028088 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIETMAN, THOMAS M, OLDENBURG, CATHERINE ELIZABETH · 2017 to 2022
$3.1M
NEI NIH HHS L40 EY028421NEI NIH HHS P30 EY002162NEI NIH HHS R01 EY025350NEI NIH HHS UG1 EY028088NIMH NIH HHS R25 MH083620
6 · The paper itself

Abstract

backgroundIn many infectious diseases, a core group of individuals plays a disproportionate role in transmission. If these individuals were effectively prevented from transmitting infection, for example with a perfect vaccine, then the disease would disappear in the remainder of the community. No vaccine has yet proven effective against the ocular strains of chlamydia that cause trachoma. However, repeated treatment with oral azithromycin may be able to prevent individuals from effectively transmitting trachoma. METHODOLOGY/PRINCIPAL

findingsHere we assess several methods for identifying a core group for trachoma, assuming varying degrees of knowledge about the transmission process. We determine the minimal core group from a completely specified model, fitted to results from a large Ethiopian trial. We compare this benchmark to a core group that could actually be identified from information available to trachoma programs. For example, determined from the rate of return of infection in a community after mass treatments, or from the equilibrium prevalence of infection. CONCLUSIONS/SIGNIFICANCE: Sufficient groups are relatively easy for programs to identify, but will likely be larger than the theoretical minimum.

Indexed as

Disease Transmission, InfectiousAdolescentAdultAnti-Bacterial AgentsAzithromycinChildChild, PreschoolEthiopiaFemaleHumansInfantInfant, NewbornMaleMass Drug AdministrationMiddle AgedPrevalenceAnti-Bacterial AgentsAzithromycin

Identifiers

PMID30296259
PMCPMC6175502
OpenAlexW2894661034

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.